CLSN - Celsion Corporation
| Previous Close | 1.9000 |
| Open | 1.8800 |
| Bid | 1.7900 x 3100 |
| Ask | 1.8600 x 2200 |
| Day's Range | 1.8200 - 1.9000 |
| 52 Week Range | 1.3500 - 3.1000 |
| Volume | 56,640 |
| Avg. Volume | 93,734 |
| Market Cap | 38.925M |
| Beta (3Y Monthly) | 1.74 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3990 |
| Earnings Date | May 18, 2017 - May 19, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.67 |
- Thomson Reuters StreetEvents
Edited Transcript of CLSN earnings conference call or presentation 15-Aug-19 3:00pm GMT
Q2 2019 Celsion Corp Earnings Call
- GlobeNewswire
Celsion Corporation Reports Second Quarter 2019 Financial Results and Provides Business Update
First Pre-Planned Efficacy Analysis of the Phase III OPTIMA Study Planned for Mid-October Strong Balance Sheet Plus the Non-Dilutive Sale of $4 Million of New.
- GlobeNewswire
Celsion Announces Publication of Results of National Institutes of Health (NIH) Analysis of ThermoDox® in Journal of Vascular and Interventional Radiology
NIH’s Independent Analysis of Celsion’s Phase III HEAT Study Confirms Increasing Radiofrequency Ablation (RFA) Heating Time + ThermoDox® Improves Overall Survival with.
- GlobeNewswire
Celsion's GEN-1 Immunotherapy Highlighted in Oppenheimer's Expert Call on Ovarian Cancer Treatment Landscape and Emerging Opportunities
Celsion Corporation (CLSN), an oncology drug-development company, announces that Premal H. Thaker, M.D., MSc., Professor of Obstetrics and Gynecology-Division of Gynecologic Oncology at Washington University School of Medicine in St. Louis, led an expert call on the ovarian cancer treatment landscape and emerging opportunities hosted by Oppenheimer & Co. Inc. on August 8th. Dr. Thaker is active in the development of GEN-1, Celsion’s DNA-based, IL-12 immunotherapy for the treatment of ovarian cancer.
- GlobeNewswire
Celsion Corporation to Hold Second Quarter 2019 Financial Results Conference Call on Thursday, August 15, 2019
LAWRENCEVILLE, N.J., Aug. 08, 2019 -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the.
- Zacks
Will Celsion (CLSN) Report Negative Q2 Earnings? What You Should Know
Celsion (CLSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Celsion Announces Data Lock for First Interim Analysis in OPTIMA Phase III Study of ThermoDox® in Primary Liver Cancer
Celsion Corporation (CLSN), an oncology drug-development company, announces the prescribed number of events has been reached for the first prespecified interim analysis of the OPTIMA Phase III Study with ThermoDox® plus RFA (radiofrequency ablation) in patients with hepatocellular carcinoma (HCC), or primary liver cancer. Following preparation of the data, the first interim analysis will be conducted by the Independent Data Monitoring Committee (iDMC). The Company expects the iDMC meeting to occur by mid-October.
- Simply Wall St.
Before You Buy Celsion Corporation (NASDAQ:CLSN), Consider Its Volatility
If you own shares in Celsion Corporation (NASDAQ:CLSN) then it's worth thinking about how it contributes to the...
- GlobeNewswire
Celsion Announces IRB Approval to Begin a Clinical Study of ThermoDox® Plus High Intensity Focused Ultrasound in Breast Cancer Patients at University Medical Center Utrecht in the Netherlands
Celsion Corporation (CLSN), an oncology drug-development company, announces that the University Medical Center Utrecht in the Netherlands has received Institutional Review Board (IRB) approval to begin a Phase I study to determine the safety, tolerability and feasibility of ThermoDox® (lyso-thermosensitive liposomal doxorubicin) in combination with Magnetic Resonance Guided High Intensity Focused Ultrasound (MR-HIFU) hyperthermia and cyclophosphamide therapy for the local treatment of the primary tumor in metastatic breast cancer (mBC).
- Thomson Reuters StreetEvents
Edited Transcript of CLSN earnings conference call or presentation 15-May-19 3:00pm GMT
Q1 2019 Celsion Corp Earnings Call
- ACCESSWIRE
Celsion Corp. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 15, 2019 / Celsion Corp. (NASDAQ: CLSN ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 15, 2019 at 11:00 AM Eastern Time. ...
- GlobeNewswire
Celsion Corporation Reports First Quarter 2019 Financial Results and Provides Business Update
Company to Hold Conference Call on Wednesday, May 15, 2019 at 11:00 a.m. EDT LAWRENCEVILLE, N.J, May 15, 2019 -- Celsion Corporation (NASDAQ: CLSN), an oncology drug.
- Zacks
Is Celsion (CLSN) Stock Outpacing Its Medical Peers This Year?
Is (CLSN) Outperforming Other Medical Stocks This Year?
- Zacks
Blueprint Medicines (BPMC) Q1 Earnings & Sales Lag Estimates
Blueprint Medicines (BPMC) posts wider-than-expected loss in first-quarter while sales miss estimates.
- Zacks
Spectrum Pharma (SPPI) Q1 Earnings Lag Estimates, Revenues Nil
Spectrum Pharma (SPPI) misses bottom-line estimates in the first quarter. The company completes sale of its marketed portfolio in March.
- Zacks
Puma Biotech (PBYI) Q1 Earnings Top, Nerlynx Disappoints
Puma Biotech (PBYI) incurs narrower loss in Q1. Sales of Nerlynx fall short of expectations due to higher discontinuations. Stock plunges 32.5%.
- Zacks
IVERIC bio's (ISEE) Q1 Loss Narrows, Gene Therapy in Focus
IVERIC bio (ISEE) first-quarter earnings beat estimates. The company is focusing on developing gene therapies for treating inherited retinal diseases.
- Zacks
Sarepta (SRPT) Q1 Earnings Top Estimates, Exondys 51 Sales Up
Sarepta (SRPT) beats estimates for both earnings and sales in first-quarter 2019. Exondys 51 continues to perform well on strong demand. Shares up.
- Zacks
Arena Pharmaceuticals' (ARNA) Loss Widens in Q1 But Stock Up
Arena Pharmaceuticals (ARNA) reports loss in the first quarter of 2019 on an adjusted basis. Revenues of $801.1 million include upfront payment of $800 million from United Therapeutics.
- GlobeNewswire
Celsion Corporation to Hold First Quarter 2019 Financial Results Conference Call on Wednesday, May 15, 2019
LAWRENCEVILLE, N.J., May 08, 2019 -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the.
- Zacks
Will Celsion (CLSN) Report Negative Earnings Next Week? What You Should Know
Celsion (CLSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Celsion (CLSN) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Celsion (CLSN) closed at $2.19, marking a -1.79% move from the previous day.
- Zacks
Celsion (CLSN) Flat As Market Sinks: What You Should Know
Celsion (CLSN) closed at $2.20 in the latest trading session, marking no change from the prior day.
- Zacks
Medicines Company (MDCO) Q1 Loss Narrows, Inclisiran in Focus
The Medicines Company (MDCO) suffers narrower-than-expected loss in Q1. The company progresses well with its sole pipeline candidate, inclisiran.
- Zacks
AstraZeneca's (AZN) Q1 Earnings Beat, New Drugs Drive Sales
AstraZeneca (AZN) beats earnings and sales estimates in the first quarter. New drugs, especially cancer drugs, drive revenues.
